PTEN and gastrointestinal stromal tumor: Clinically low-/intermediate-risk GIST patients with PTEN low expression/PTEN loss may benefit from intensive surveillance, whereas clinically high-risk GIST patients with PTEN low expression/PTEN loss may benefit from further clinical trials to investigate the additional value of mTOR inhibitors to standard adjuvant TKIs.